Navigation Links
Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
Date:11/11/2007

(PHILADELPHIA) An immune system messenger molecule that normally helps quiet inflammation could be an effective tool against multiple sclerosis (MS). Neurology researchers led by Abdolmohamad Rostami, M.D., Ph.D., professor and chair of the Department of Neurology at Jefferson Medical College of Thomas Jefferson University and the Jefferson Hospital for Neuroscience in Philadelphia, have found that the protein interkeukin-27 (IL-27) helped block the onset or reverse symptoms in animals with an MS-like disease.

The results suggest that IL-27 may someday be part of a therapy to temper over-active immune responses, which are thought to be at the heart of MS, an autoimmune disease (in which the body attacks its own tissue) affecting the central nervous system. The Jefferson neuroscientists report their findings November 11, 2007 in the journal Nature Immunology. The paper first appears in an advance online publication.

In MS, one of the most common neurological diseases affecting young adults, the myelin coating of nerve fibers becomes inflamed and scarred. As a result, messages cannot be sent through the nervous system. Dr. Rostamis team was trying to understand the mechanisms of how immune responses damage the myelin sheath and axons in the brain.

They had previously observed that IL-27, a signaling molecule called a cytokine, could suppress IL-17, another cytokine, and inflammation. They also knew that in other MS models, mice that lacked receptors for IL-27 developed excessive inflammation.

Dr. Rostami, who is also director of the Neuroimmunology Laboratory in the Department of Neurology at Jefferson Medical College, Denise Fitzgerald, Ph.D., a postdoctoral research fellow in Dr. Rostamis laboratory, and their colleagues used an animal model of MS called experimental autoimmune encephalomyelitis (EAE) for the investigation.

When the scientists gave IL-27 to the experimental mice, it significantly suppressed active disease. They saw similar effects from IL-27 in cultured cells that were transferred into nave animals, which then produced significantly milder disease. At the same time, they also showed that IL-27 enhanced the production of IL-10, a crucial anti-inflammatory cytokine.

We previously showed that IL-27 could suppress IL-17, he notes. Here we also show that IL-27 can enhance the production of IL-10. These may both be different and complementary mechanisms by which IL-27 can suppress EAE.

The findings suggest that increasing IL-27 concentrations might raise IL-10 levels, and help quell an over-active immune response. This is the first time that we have direct evidence that by actively giving IL-27 like a drug, we can suppress EAE in mice.

Dr. Rostami explains that after an MS flare-up, patients recover from the disease, though the reasons are poorly understood. We think that one of the ways that recovery from a disease flare-up occurs is that part of the immune system is shut off, suppressing the immune response in the brain. IL-27 appears to be crucial in this process, he says.

The team would like to study MS patients blood samples to see if similar processes are at work, Dr. Rostami notes. If we get similar findings in human disease, then perhaps IL-27 could be used therapeutically as a compound to suppress inflammation in the brains of MS patients.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
2. Jefferson immunology researchers halt lethal rabies infection in brain
3. Jefferson radiation oncologists use real-time system to plant seeds against cancer
4. Jefferson researchers find personalized interventions key to improving colon cancer screening rates
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
7. Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
10. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
11. New class of RNA molecules may be important in human cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... IsoComforter, Inc., ... introduction of the innovative newly improved Iso-Hip Wrap. The newly designed hip ... design enhances comfort and enables the patient to enjoy the benefits of cold ...
(Date:5/4/2016)... ... ... The Spiritual Care Association (SCA) has declared May 10, 2016 ... and their families, and their overall contribution to the health care system. It will ... sent “Thank You Chaplain” cards with hand-painted artwork to about 10,000 chaplains and pastoral ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, ... Society™ and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful ... planning tools to attendees and exhibitors for the 2016 WOCN Society & CAET ...
(Date:5/4/2016)... LA (PRWEB) , ... May 04, 2016 , ... Hight-Doland ... LA area has teamed up with Big Brothers Big Sisters of Southwest Louisiana to ... being accepted here . , Big Brothers Big Sisters of Southwest Louisiana has ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today announced its tenth anniversary ... What started out as an idea to provide a holistic approach to wellness ... , Developed by Dr. David Swanekamp, Chiropractic Physician , the wellness center offers ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Mich. , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that ... company released a video of two patients who tell their personal story and encourage those ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... JERUSALEM , May 3, 2016 ... (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the ... Clinical and Regulatory Affairs. "Ms. Strauss-Levy has ... affairs, and has established an outstanding track record, having ... development and regulatory approval processes in the ...
(Date:5/2/2016)... 2, 2016 Kalorama Information noted the 5 ... market in a recent white paper.  The healthcare market ... usage, a growing market are among the top drivers ... report EMR 2016: The Market for Electronic ... complete study of the EMR industry, and the report ...
Breaking Medicine Technology: